The Fort Worth Press - Emerging Growth Research Releases Q1:26 Quarterly Update on SBC Medical Group; Upgrades to Buy Rating and Increases Price Target to $10.00

USD -
AED 3.672497
AFN 63.000241
ALL 82.171465
AMD 368.348897
ANG 1.79046
AOA 918.000389
ARS 1398.488498
AUD 1.402652
AWG 1.80225
AZN 1.702334
BAM 1.686369
BBD 2.01471
BDT 122.938169
BGN 1.66992
BHD 0.377402
BIF 3020.685136
BMD 1
BND 1.280857
BOB 6.911715
BRL 5.029503
BSD 1.000285
BTN 96.802814
BWP 13.565621
BYN 2.74451
BYR 19600
BZD 2.011778
CAD 1.375785
CDF 2252.50141
CHF 0.790105
CLF 0.022951
CLP 903.339761
CNY 6.815035
CNH 6.806945
COP 3794.6
CRC 452.072394
CUC 1
CUP 26.5
CVE 95.074886
CZK 20.965798
DJF 178.130146
DKK 6.44231
DOP 58.86512
DZD 133.019018
EGP 53.394199
ERN 15
ETB 162.413668
EUR 0.86205
FJD 2.206102
FKP 0.746313
GBP 0.746145
GEL 2.670307
GGP 0.746313
GHS 11.553153
GIP 0.746313
GMD 72.999863
GNF 8768.980056
GTQ 7.62565
GYD 209.188029
HKD 7.832795
HNL 26.605275
HRK 6.493303
HTG 130.939755
HUF 311.467
IDR 17702
ILS 2.9233
IMP 0.746313
INR 96.81545
IQD 1310.346017
IRR 1320950.000336
ISK 123.620207
JEP 0.746313
JMD 158.255516
JOD 0.709019
JPY 159.029504
KES 129.570073
KGS 87.44985
KHR 4025.798219
KMF 424.000072
KPW 899.971581
KRW 1505.610135
KWD 0.30932
KYD 0.833614
KZT 471.964269
LAK 21911.241022
LBP 89576.467748
LKR 344.602809
LRD 183.053536
LSL 16.605103
LTL 2.95274
LVL 0.60489
LYD 6.365917
MAD 9.237263
MDL 17.385344
MGA 4199.970684
MKD 53.148469
MMK 2099.263265
MNT 3579.713688
MOP 8.070738
MRU 39.951887
MUR 47.41059
MVR 15.402442
MWK 1734.481837
MXN 17.368402
MYR 3.969304
MZN 63.909628
NAD 16.605103
NGN 1372.909756
NIO 36.809022
NOK 9.27905
NPR 154.884158
NZD 1.71029
OMR 0.384497
PAB 1.000285
PEN 3.424041
PGK 4.36121
PHP 61.698032
PKR 278.657234
PLN 3.66772
PYG 6163.290997
QAR 3.637963
RON 4.511497
RSD 101.201969
RUB 71.15218
RWF 1463.566052
SAR 3.752456
SBD 8.032258
SCR 14.092325
SDG 600.498241
SEK 9.377065
SGD 1.280295
SHP 0.746601
SLE 24.604613
SLL 20969.502105
SOS 571.667536
SRD 37.227501
STD 20697.981008
STN 21.124878
SVC 8.752597
SYP 110.544495
SZL 16.593807
THB 32.679506
TJS 9.292705
TMT 3.5
TND 2.933944
TOP 2.40776
TRY 45.597335
TTD 6.780655
TWD 31.621099
TZS 2605.00299
UAH 44.286108
UGX 3775.74864
UYU 40.326961
UZS 12083.430335
VES 517.3145
VND 26373
VUV 118.270619
WST 2.715865
XAF 565.592316
XAG 0.013231
XAU 0.000222
XCD 2.70255
XCG 1.802771
XDR 0.702153
XOF 565.592316
XPF 102.830734
YER 238.650163
ZAR 16.593197
ZMK 9001.197693
ZMW 18.930478
ZWL 321.999592
  • CMSC

    0.0100

    22.81

    +0.04%

  • GSK

    -0.1000

    50.95

    -0.2%

  • JRI

    0.1000

    12.57

    +0.8%

  • CMSD

    0.0950

    22.845

    +0.42%

  • BCC

    0.9400

    66.41

    +1.42%

  • BCE

    0.1550

    24.135

    +0.64%

  • RIO

    1.3600

    102.28

    +1.33%

  • NGG

    0.8500

    85

    +1%

  • RYCEF

    0.8800

    16.25

    +5.42%

  • VOD

    0.1150

    15.265

    +0.75%

  • AZN

    3.0000

    187.64

    +1.6%

  • RBGPF

    0.7200

    63.23

    +1.14%

  • BP

    -0.5800

    45.56

    -1.27%

  • RELX

    -0.4210

    33.159

    -1.27%

  • BTI

    -0.2450

    65.815

    -0.37%

Emerging Growth Research Releases Q1:26 Quarterly Update on SBC Medical Group; Upgrades to Buy Rating and Increases Price Target to $10.00
Emerging Growth Research Releases Q1:26 Quarterly Update on SBC Medical Group; Upgrades to Buy Rating and Increases Price Target to $10.00

Emerging Growth Research Releases Q1:26 Quarterly Update on SBC Medical Group; Upgrades to Buy Rating and Increases Price Target to $10.00

NEW YORK CITY, NY / ACCESS Newswire / May 20, 2026 / Emerging Growth Research today announced the release of its Q1:26 Quarterly Update Report on SBC Medical Group Holdings, Inc. (NASDAQ:SBC), upgrading the Company to a Buy rating and increasing its 12-month price target to $10.00 from $9.00, representing significant potential upside from the Company's recent share price of $2.89 as of May 19, 2026.

Text size:

The Quarterly Update highlights SBC's expectation for a return to revenue growth in 2026 following the completion of pricing-related headwinds experienced during 2025, while emphasizing the Company's strong cash position, expanding clinic footprint, and long-term global growth strategy.

Key Highlights from the Q1:26 Quarterly Update:

  • Return to Growth Expected in 2026: Emerging Growth Research believes the impact of SBC's early-2025 franchise fee restructuring is now largely absorbed, positioning the Company for renewed revenue growth beginning in 2026.

  • Underlying Business Trends Remain Strong: Q1:26 same-clinic sales increased +6% year-over-year, while customer growth rose +10% year-over-year to approximately 6.7 million annual visits with a 72% repeat rate.

  • Sequential Improvement in Financial Results: While Q1:26 revenue declined 9% year-over-year to $43.1 million, revenue increased +9% sequentially from Q4:25. Operating profit also increased +38% sequentially.

  • Significant Cash Position Supports Expansion: SBC ended Q1:26 with approximately $167 million in cash and only modest debt levels, leaving the Company with a strong net cash position relative to its market capitalization.

  • Continued Clinic Expansion: SBC expanded its clinic network to 284 locations, up +13% year-over-year, as management continues to pursue its long-term objective of reaching 1,000 clinics globally over the next nine years.

  • International Expansion and New Growth Initiatives: The Company continues to pursue strategic M&A opportunities in Japan, Southeast Asia, and the United States while also investing in AI-driven operational initiatives and longevity-focused wellness services.

  • Improved Trading Liquidity: Emerging Growth Research noted that the founder's recent partial share sale increased public float and trading liquidity while maintaining strong founder alignment with shareholders.

  • Attractive Valuation: Emerging Growth Research believes SBC shares remain materially undervalued relative to the Company's long-term earnings potential, strong operating margins, and substantial net cash position.

For a copy of the full Q1:26 Quarterly Update Report, please visit:

https://storage.googleapis.com/accesswire/media/1168563/sbcq126-quarterly-update-052026.pdf

or

https://www.emerginggrowth.com/profile/sbc/ (on the right side of the page as you scroll down)

About SBC Medical Group Holdings, Inc.

SBC Medical Group Holdings, Inc. provides management services to cosmetic treatment centers through a franchise model operating across Japan, Southeast Asia, and the United States. The Company operates a diversified portfolio of cosmetic, dermatology, and wellness-focused brands and continues to expand through both organic growth and strategic acquisitions.

About Emerging Growth Research

Emerging Growth Research is an independent equity research firm providing institutional-quality analysis on emerging growth companies.

Contact:

Emerging Growth Research
[email protected]
https://www.emerginggrowth.com

Forward-Looking Statements

This press release contains forward-looking statements concerning business operations, financial performance, growth initiatives, and future expectations of SBC Medical Group Holdings, Inc. These statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected.

SOURCE: SBC Medical Group Holdings Incorporated



View the original press release on ACCESS Newswire

G.George--TFWP